

In the claims:

Please cancel claims 2-6, 8-9, 15-21, 23, 25-28, 33-38, 40-67, and 69-114 without prejudice or disclaimer of the subject matter thereof. Please amend claims 7, 22, 24, 29, 30, 31, 32, 39, and 68 as shown below. Please insert new claims 115-119 as shown below.

1. (Original) A method, comprising:
applying to a localized region of a body of a patient a binding partner immobilized relative to or able to be immobilized relative to a signaling entity; and determining immobilization of the signaling entity within or on the body of the patient.

2-6. (Canceled)

7. (Currently amended) A method as in ~~claims 1 or 2~~ claim 1, wherein the patient is undergoing surgical procedure.

8-9. (Canceled)

10. (Original) A method as in claim 7, wherein the surgical procedure is a minimally-invasive procedure.

11. (Original) A method as in claim 7, wherein the surgical procedure is an endoscopic or laproscopic procedure.

12. (Original) A method as in claim 7, wherein the surgical procedure involves removal of a diseased tissue.

13. (Original) A method as in claim 12, wherein the diseased tissue comprises a cancerous cell.

14. (Original) A method as in claim 12, wherein the diseased tissue comprises a tumor.

15-21. (Canceled)

22. (Currently amended) A method ~~or a kit~~ as in ~~any of claims 1-6~~ claim 1, wherein the binding partner is a biological binding partner.

23. (Canceled)

24. (Currently amended) A method ~~or a kit~~ as in ~~any of claims 1-6~~ claim 1, wherein the binding partner is an antibody.

25-28. (Canceled)

29. (Currently amended) A method ~~or a kit~~ as in ~~any of claims 1-6~~ claim 1, wherein the signaling entity is able to absorb or emit electromagnetic radiation.

30. (Currently amended) A method ~~or a kit~~ as in ~~any of claims 1-6~~ claim 1, wherein the signaling entity is electronically detectable.

31. (Currently amended) A method ~~or a kit~~ as in ~~any of claims 1-6~~ claim 1, wherein the signaling entity is chemically detectable.

32. (Currently amended) A method ~~or a kit~~ as in claim 29, wherein the signaling entity is fluorescent.

33-38. (Canceled)

39. (Currently amended) A method as in ~~claims 1 or 2~~ claim 1, wherein the determining step comprises optically detecting the signaling entity.

40-67. (Canceled)

68. (Currently amended) A method ~~or a kit~~ as in ~~claims 44-48~~ claim 1 wherein an agglomeration of colloid particles acts as a signaling entity.

69-114. (Canceled)

115. (New) A method of claim 1, wherein the binding partner is a chemical compound.

116. (New) A method of claim 1, wherein the binding partner is specific for a cell receptor.

117. (New) A method of claim 1, wherein the cell receptor is MUC1.

118. (New) A method of claim 24, wherein the antibody is specific for a cell receptor.

119. (New) A method of claim 118, wherein the cell receptor is MUC1